Skip to content
Screener

Innoviva, Inc. INVA Q2 2026 earnings

Reported August 5, 2026 · After market close

Revenue$119.6MBeat by $8.6M
EPS$1.14Beat by $0.70
Revenue estimate$111.0M
EPS estimate$0.44
“Innoviva delivered another strong quarter, supported by durable cash generation from our royalty portfolio and continued excellent commercial momentum at IST, which achieved 46% year-over-year net product sales growth, including 26% growth in U.S. sales. We remain on track to achieve at least $150 million in IST U.S. net product sales in 2026, reflecting the differentiation of our marketed critical care and infectious disease portfolio and robust execution. Recently, we also advanced several growth opportunities. This quarter, we announced a commercialization and licensing agreement with Dr. Reddy's Laboratories, expanding access to our top-performing antibiotic, XACDURO, in emerging markets. Additionally, we launched Nortiva Bio, a novel platform for long-acting oral medicine delivery, with large upside potential.”
Pavel Raifeld

Next report

Nov 4, 2026 (in a month)
Revenue estimate$115.3M
EPS estimate$0.49

Financials

Q2 2026

Income statement

See full
Revenue$119.6M+19.3%
Gross profit$90.6M+9.0%
Operating income$50.9M+4.3%
Net income-$83.4M-231%
EPS (diluted)-$1.14-248%

Balance sheet

See full
Cash & equivalents$570.4M+43.5%
Total debt$269.7M-40.2%
Total equity$1.2B—
Total assets$1.7B+27.7%

Cash flow

See full
Operating cash flow$52.0M+17.9%
CapEx$429.0K—
Free cash flow$51.5M+16.9%

Valuation & ratios

Valuation

as of 10/02/26
See full
Market cap$1.48B+33.4%
Enterprise value$1.18B+32.3%
P/E4.2×-4.6×
P/S3.4×+0.5×

Profitability

See full
Gross margin72.2%-10.9pp
Operating margin36.9%-10.7pp
Net margin81.2%+70.8pp
FCF margin43.1%-11.1pp

Returns & leverage

See full
Debt / equity0.2×—
Current ratio16×+13.4×

Segments

By product

See full
Giapreza$22.3M+28.7%
Cost Reimbursement$1.8M+125%

FAQ

When did Innoviva, Inc. report Q2 2026 earnings?
Innoviva, Inc. (INVA) reported Q2 2026 earnings on August 5, 2026 after market close.
What were Innoviva, Inc.'s Q2 2026 revenue and EPS?
Innoviva, Inc. reported revenue of $119.6M and eps of $1.14 for Q2 2026.
Did Innoviva, Inc. beat estimates in Q2 2026?
Revenue beat the consensus estimate of $111.0M by $8.6M. EPS beat the consensus estimate of $0.44 by $0.70.
How did Innoviva, Inc.'s Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 19.3% from $100.3M a year earlier and eps grew 48.1% from $0.77.
Where can I find Innoviva, Inc.'s Q2 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-335192) and the 10-Q periodic report (0001193125-26-335235) directly on SEC EDGAR. The filing index links above go to sec.gov.